2023
Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020
Li D, Laine L, Shung D. Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. The American Journal Of Medicine 2023, 136: 1179-1186.e1. PMID: 37696350, PMCID: PMC10841721, DOI: 10.1016/j.amjmed.2023.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCardiovascular DiseasesEmergency Service, HospitalGastrointestinal HemorrhageHumansMedicarePrimary PreventionRisk FactorsUnited StatesConceptsUpper gastrointestinal bleedingGastrointestinal bleedingRed blood cell transfusionNationwide Emergency Department SamplePrimary cardiovascular preventionRecent guideline recommendationsBlood cell transfusionProportion of hospitalizationsEmergency Department SampleMedicare reimbursementInternational Statistical ClassificationRelated Health ProblemsCardiovascular preventionCell transfusionOlder patientsHospital admissionCommon etiologyGuideline recommendationsMajor complicationsUlcer diseaseEndoscopic interventionRevision codesAppropriate indicationsRecent guidelinesCardiovascular disease
2022
Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis
Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, Sengupta N, Yang YX, Scheiman J, Laine L. Association of Antisecretory Drugs with Upper Gastrointestinal Bleeding in Patients Using Oral Anticoagulants: A Systematic Review and Meta-Analysis. The American Journal Of Medicine 2022, 135: 1231-1243.e8. PMID: 35679879, PMCID: PMC10031639, DOI: 10.1016/j.amjmed.2022.05.031.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsAnti-Inflammatory Agents, Non-SteroidalAspirinGastrointestinal AgentsGastrointestinal HemorrhageHistamine H2 AntagonistsHumansObservational Studies as TopicProton Pump InhibitorsConceptsUpper gastrointestinal bleedingProton pump inhibitorsGastrointestinal bleedingH2-receptor antagonistsObservational studyOral anticoagulantsAntisecretory drugsRelative riskLower riskNonsteroidal anti-inflammatory drug useSystematic reviewAnti-inflammatory drug useOvert upper gastrointestinal bleedingLow statistical heterogeneitySingle observational studyGreater treatment effectRandom-effects modelWeb of ScienceConcomitant aspirinRandomized trialsCochrane LibraryPump inhibitorsBias assessmentStatistical heterogeneityBleeding
2018
Editorial: gastrointestinal safety of COX‐2 selective and nonselective NSAIDs—the impact of the PRECISION trial
Laine L. Editorial: gastrointestinal safety of COX‐2 selective and nonselective NSAIDs—the impact of the PRECISION trial. Alimentary Pharmacology & Therapeutics 2018, 47: 1545-1546. PMID: 29878414, DOI: 10.1111/apt.14642.Commentaries, Editorials and LettersMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalArthritisCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsHumansIbuprofenNaproxenEffects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials
Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanas A, Patrono C, Baigent C. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology & Hepatology 2018, 3: 231-241. PMID: 29475806, PMCID: PMC5842491, DOI: 10.1016/s2468-1253(18)30037-2.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsHistamine H2 AntagonistsHumansPeptic UlcerPeptic Ulcer HemorrhageProstaglandins, SyntheticProton Pump InhibitorsSecondary PreventionConceptsProton pump inhibitorsUpper gastrointestinal bleedingPeptic ulcer diseaseAcute upper gastrointestinal bleedingGastrointestinal bleedingUlcer diseasePrevention trialsHealing trialsBlood transfusionClinical circumstancesProstaglandin analoguesHistamine-2 receptor antagonistsParticular proton pump inhibitorsNon-steroidal anti-inflammatory drugsEndoscopic ulcer healingDifferent clinical circumstancesUK Medical Research CouncilBritish Heart FoundationDifferent clinical settingsAnti-inflammatory drugsSmall study biasFurther endoscopic interventionMedical Research CouncilLarge protective effectEndoscopic ulcers
2016
Upper Gastrointestinal Bleeding Due to a Peptic Ulcer
Laine L. Upper Gastrointestinal Bleeding Due to a Peptic Ulcer. New England Journal Of Medicine 2016, 374: 2367-2376. PMID: 27305194, DOI: 10.1056/nejmcp1514257.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLong-Term PPI Use: Balancing Potential Harms and Documented Benefits
Laine L, Nagar A. Long-Term PPI Use: Balancing Potential Harms and Documented Benefits. The American Journal Of Gastroenterology 2016, 111: 913. PMID: 27113114, DOI: 10.1038/ajg.2016.156.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2014
NSAID-Associated Gastrointestinal Bleeding: Assessing the Role of Concomitant Medications
Laine L. NSAID-Associated Gastrointestinal Bleeding: Assessing the Role of Concomitant Medications. Gastroenterology 2014, 147: 730-733. PMID: 25167988, DOI: 10.1053/j.gastro.2014.08.021.Commentaries, Editorials and LettersAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase InhibitorsGastrointestinal HemorrhageHumans
2011
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2011, 107: ajg2011443. PMID: 22186979, PMCID: PMC3321505, DOI: 10.1038/ajg.2011.443.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsChi-Square DistributionDouble-Blind MethodDrug CombinationsDuodenal UlcerEndoscopy, GastrointestinalFamotidineFemaleHumansIbuprofenMaleMiddle AgedProportional Hazards ModelsRisk FactorsStomach UlcerTreatment OutcomeConceptsPrimary end point analysisNon-steroidal anti-inflammatory drugsUpper GI ulcersDuodenal ulcerGI ulcersGastric ulcerEnd-point analysisDaily non-steroidal anti-inflammatory drugsH. pylori stool testDouble-blind randomized trialsMultiple potential risk factorsReduction of gastricSingle-tablet combinationUpper gastrointestinal ulcersDouble-blind trialProportional hazards analysisPotential risk factorsAnti-inflammatory drugsBaseline endoscopyREDUCE studyStudy endoscopyTablets thriceUlcer complicationsStool testRandomized trialsEvaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune K. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal Of Rheumatology 2011, 38: 1071-8. PMID: 21459935, DOI: 10.3899/jrheum.100880.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidBiomarkersCardiovascular DiseasesC-Reactive ProteinDiclofenacEtoricoxibFemaleHeart FailureHumansLongitudinal StudiesMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainOsteoarthritisPeptide FragmentsProspective StudiesPyridinesRetrospective StudiesRisk FactorsSulfonesThrombosisTreatment OutcomeConceptsHigh-sensitivity C-reactive proteinNonsteroidal antiinflammatory drugsSensitivity C-reactive proteinNT-proBNPC-reactive proteinHeart failureCV eventsCV outcomesCV riskThrombotic eventsMyocardial infarctionAntiinflammatory drugsBiomarkers N-terminal pro-B-type natriuretic peptideCardiac biomarkers N-terminal pro-B-type natriuretic peptideN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic nonsteroidal antiinflammatory drugsBaseline NT-proBNPChronic NSAID treatmentLow CV riskNT-proBNP levelsFuture cardiovascular eventsBody mass indexIdentification of patientsTypes of arthritis
2010
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal Of Gastroenterology 2010, 105: 2533. PMID: 21131924, DOI: 10.1038/ajg.2010.445.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnti-Inflammatory Agents, Non-SteroidalAryl Hydrocarbon HydroxylasesAspirinCardiovascular DiseasesClopidogrelCytochrome P-450 CYP2C19Drug InteractionsDrug Therapy, CombinationGastrointestinal HemorrhageHistamine H2 AntagonistsHumansPiperazinesPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRisk FactorsThienopyridinesThiophenesTiclopidineACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Documents A, Abraham N, Hlatky M, Antman E, Bhatt D, Bjorkman D, Clark C, Furberg C, Johnson D, Kahi C, Laine L, Mahaffey K, Quigley E, Scheiman J, Sperling L, Tomaselli G. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal Of The American College Of Cardiology 2010, 56: 2051-2066. PMID: 21126648, DOI: 10.1016/j.jacc.2010.09.010.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Members W, Abraham N, Hlatky M, Antman E, Bhatt D, Bjorkman D, Clark C, Furberg C, Johnson D, Kahi C, Laine L, Mahaffey K, Quigley E, Scheiman J, Sperling L, Tomaselli G. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 2010, 122: 2619-2633. PMID: 21060077, DOI: 10.1161/cir.0b013e318202f701.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnti-Inflammatory Agents, Non-SteroidalAryl Hydrocarbon HydroxylasesAspirinCardiovascular DiseasesClopidogrelCytochrome P-450 CYP2C19Drug InteractionsDrug Therapy, CombinationGastrointestinal HemorrhageHistamine H2 AntagonistsHumansPiperazinesPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRisk FactorsThienopyridinesThiophenesTiclopidineRisk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients. Alimentary Pharmacology & Therapeutics 2010, 32: 1240-1248. PMID: 20955443, DOI: 10.1111/j.1365-2036.2010.04465.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalArthritisCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibFemaleGastrointestinal DiseasesHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesPyridinesRisk FactorsSulfonesTime FactorsUpper Gastrointestinal TractConceptsClinical eventsRisk factorsLow-dose aspirin useDouble-blind randomized trialsLong-term prospective studiesCox proportional hazards modelNonsteroidal anti-inflammatory drugsDiscontinuation of NSAIDsPredictors of discontinuationUpper GI eventsLow-dose aspirinPotential risk factorsProportional hazards modelAnti-inflammatory drugsAspirin useGI eventsPatient characteristicsArthritis patientsTreat analysisRandomized trialsRheumatoid arthritisProspective studyGI effectsDyspepsiaHazards model
2009
Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines
LAINE L, CONNORS L, GRIFFIN MR, CURTIS SP, KAUR A, CANNON CP. Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Alimentary Pharmacology & Therapeutics 2009, 30: 767-774. PMID: 19594486, DOI: 10.1111/j.1365-2036.2009.04090.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsArthritisDrug PrescriptionsDrug Therapy, CombinationEpidemiologic MethodsFemaleGastrointestinal DiseasesGuideline AdherenceHumansMaleMiddle AgedPractice Guidelines as TopicUnited StatesFactors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study
Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. Journal Of Hypertension 2009, 27: 886-893. PMID: 19516186, DOI: 10.1097/hjh.0b013e328325d831.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidBlood PressureCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibFemaleHumansHypertensionMaleMiddle AgedMultivariate AnalysisOsteoarthritisPyridinesSulfonesConceptsCalcium channel blockersHistory of hypertensionBlood pressureAntihypertensive classesDiastolic BPRisk factorsAntihypertensive drug classesHypertension risk factorsDiastolic blood pressureSystolic blood pressureBlood pressure changesAntihypertensive medicationsMultinational EtoricoxibNSAID therapyHypertensive effectAntihypertensive effectArthritis patientsDrug classesChannel blockersNonsignificant decreaseMultivariate analysisSBPLong-term studiesEtoricoxibHypertensionHow Common Is Diclofenac-Associated Liver Injury? Analysis of 17,289 Arthritis Patients in a Long-Term Prospective Clinical Trial
Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How Common Is Diclofenac-Associated Liver Injury? Analysis of 17,289 Arthritis Patients in a Long-Term Prospective Clinical Trial. The American Journal Of Gastroenterology 2009, 104: ajg2008149. PMID: 19174782, DOI: 10.1038/ajg.2008.149.Peer-Reviewed Original ResearchConceptsLiver-related hospitalizationsNon-steroidal anti-inflammatory drugsMonths of therapyAminotransferase elevationLiver eventsClinical trialsLong-term prospective clinical trialsLarge double-blind trialDeath/transplantHepatotoxicity of diclofenacTransplant/deathDouble-blind trialPrescribed non-steroidal anti-inflammatory drugsProspective clinical trialsAdverse hepatic effectsALT/ASTRates of laboratoryAnti-inflammatory drugsProspective trialArthritis patientsLiver injuryRheumatoid arthritisClinical eventsHepatic diseaseCausality assessment
2008
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. The American Journal Of Gastroenterology 2008, 103: ajg2008576. PMID: 18853980, DOI: 10.1111/j.1572-0241.2008.02200.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalCardiovascular DiseasesGastrointestinal DiseasesHumansPlatelet Aggregation InhibitorsConceptsNonselective nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsGI risk factorsNonsteroidal anti-inflammatory drugsCV riskHigh CV riskProton pump inhibitorsAnti-inflammatory drugsRisk factorsCyclooxygenase-2- selective nonsteroidal antiinflammatory drugsSelective nonsteroidal antiinflammatory drugsCardiovascular safety issuesMultidisciplinary international panelPatient's CV riskClinical practice recommendationsManagement of patientsAnti-platelet agentsGI complicationsCardiovascular effectsGI riskInternational working partyPump inhibitorsTreatment strategiesAntiinflammatory drugsPatientsLower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac
Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac. Gastroenterology 2008, 135: 1517-1525. PMID: 18823986, DOI: 10.1053/j.gastro.2008.07.067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalConfidence IntervalsCyclooxygenase InhibitorsDiclofenacDose-Response Relationship, DrugEtoricoxibFemaleFollow-Up StudiesGastrointestinal HemorrhageHumansIncidenceMaleMiddle AgedOdds RatioOsteoarthritisProspective StudiesPyridinesRisk FactorsSulfonesTreatment OutcomeConceptsLower GI eventsClinical eventsGI eventsRisk factorsCOX-2 selective inhibitorsBlinded adjudication committeeLower Gastrointestinal EventsTraditional NSAID diclofenacUpper GI eventsDouble-blind trialSignificant risk factorsMajor risk factorAnti-inflammatory drugsSelective inhibitorNonsteroidal anti-inflammatory drug diclofenacGastrointestinal eventsNSAID useProspective trialMultivariable analysisRheumatoid arthritisAdjudication committeeMean durationCyclo-oxygenaseNSAID diclofenacAbstractTextGastric Mucosal Defense and Cytoprotection: Bench to Bedside
Laine L, Takeuchi K, Tarnawski A. Gastric Mucosal Defense and Cytoprotection: Bench to Bedside. Gastroenterology 2008, 135: 41-60. PMID: 18549814, DOI: 10.1053/j.gastro.2008.05.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsCyclooxygenase InhibitorsGastric MucosaGastritisHumansStomach UlcerConceptsStress-related mucosal diseaseProton pump inhibitorsMucosal defenseGastric mucosal defenseMucosal injuryNoxious factorsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsGeneration of PGsImportant clinical sequelaeUpper gastrointestinal complicationsHigh-risk patientsModern intensive careAbsolute risk reductionInhibition of cyclooxygenaseAnti-inflammatory drugsContinuous blood flowGastrointestinal complicationsClinical sequelaePharmacologic therapyAntisecretory drugsSignificant bleedingAnnual incidenceIntensive careSensory innervationCOX-2 Selective Inhibitors in the Treatment of Osteoarthritis
Laine L, White WB, Rostom A, Hochberg M. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars In Arthritis And Rheumatism 2008, 38: 165-187. PMID: 18177922, DOI: 10.1016/j.semarthrit.2007.10.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTraditional nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsTreatment of osteoarthritisBlood pressureNonselective nonsteroidal antiinflammatory drugsCyclooxygenase-2 selective inhibitorCOX-2 selective inhibitorsClinical liver injuryHepatic side effectsSignificant renal dysfunctionCongestive heart failureSelective inhibitorAminotransferase elevationClinical hepatotoxicityGastrointestinal complicationsHypertensive patientsRenal dysfunctionUlcer complicationsCardiovascular riskSevere painGastroduodenal ulcersHeart failureLiver injuryOA patientsRandomized trials